Rein Therapeutics Secures Patents for Dry Powder LTI-03 in Respiratory Disease Treatment

AUSTIN, Texas, April 23, 2025 – Rein Therapeutics, a biopharmaceutical company focused on developing innovative treatments for pulmonary and fibrosis conditions, has announced the issuance of two new patents by the U.S. Patent and Trademark Office. These patents pertain to their leading product candidate, LTI-03, which is a unique synthetic peptide with a dual-action mechanism. The patents, U.S. Patent No. 12,280,088 and U.S. Patent No. 12,280,089, were granted on April 22, 2025, under the title "Dry Powder Formulation of Caveolin-1 Peptides and Methods of Use Thereof."

LTI-03 employs a dual mechanism that focuses on maintaining the viability of alveolar epithelial cells while simultaneously inhibiting fibrotic signaling. This innovative therapeutic is delivered via dry powder inhalation. The recently issued patents cover the formulation of LTI-03 as a dry powder inhalant and its therapeutic applications for a range of lung diseases. These include interstitial lung disease, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory or fibrotic lung conditions.

Brian Windsor, Ph.D., the President and CEO of Rein Therapeutics, expressed that the new patents significantly strengthen the company’s intellectual property base for their inhaled peptide program. He emphasized that these developments support the ongoing progression of LTI-03 as a potential pioneering treatment option for IPF and other chronic and acute lung conditions. Windsor highlighted the pressing unmet needs in these patient groups and announced that the company is preparing to start a Phase 2 clinical trial of LTI-03 in IPF patients within the first six months of the year.

Rein Therapeutics is a clinical-stage company that is developing a series of first-in-class treatments aimed at addressing significant unmet medical needs in the areas of orphan pulmonary and fibrosis conditions. The lead candidate, LTI-03, is notable for its dual mechanism that targets the survival of alveolar epithelial cells and inhibits profibrotic signaling. The company anticipates launching a Phase 2 clinical trial for LTI-03 targeting idiopathic pulmonary fibrosis shortly.

Additionally, Rein Therapeutics is working on another product candidate, LTI-01, which is a proenzyme that has successfully completed both Phase 1b and Phase 2a clinical trials. It is being developed for the treatment of loculated pleural effusions and has been granted Orphan Drug Designation in both the U.S. and E.U., along with a Fast Track Designation in the U.S.

These advancements mark significant milestones for Rein Therapeutics, as the company continues to push forward with its pipeline of innovative treatments designed to tackle challenging medical conditions with limited treatment options.